Objective: Evaluation of colposcopic and histopathological findings in women screened for cervical human papillomavirus deoxyribonucleic acid persistence.
Study Design: A total of 12 527 women, aged 32 to 38 years old, attending the population-based cervical cancer screening program in Sweden were randomized 1:1 to mock testing or human papillomavirus deoxyribonucleic acid testing by general primer 5+/6+ polymerase chain reaction and subsequent typing. Human papillomavirus deoxyribonucleic acid-positive women with a normal Papanicolaou smear (n=341) and an equal number from the control group were human papillomavirus tested on average 19 months later. One hundred nineteen women with type-specific human papillomavirus persistence and 111 controls were referred to colposcopy, and 84.8% attended.
Results: Histopathology from colposcopically directed biopsies confirmed cervical intraepithelial neoplasia grade 2 or 3 in 28 of 100 of the women with human papillomavirus deoxyribonucleic acid persistence and in 2 of 95 among controls.
Conclusion: Among women with normal Papanicolaou smear attending population-based screening, the positive predictive value of human papillomavirus deoxyribonucleic acid persistence for detection of biopsy-confirmed cervical intraepithelial neoplasia 2 or 3 was 29%.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajog.2005.01.056 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
U.parvum serovar 6 may be a novel element in the progression of HPV infection to CIN: A cross-sectional study of 7,058 women.
J Infect
December 2024
Microbiome Medicine Centre, Department of Laboratory Medicine, ZhuJiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Background: Ureaplasma parvum (U. parvum) is generally regarded as innocuous, and studies focusing on variations in pathogenicity among U. parvum serovars are inadequate.
View Article and Find Full Text PDFCost-effectiveness analysis of 9-valent human papillomavirus vaccine combined with screening for cervical cancer in Japan.
Int J Gynaecol Obstet
December 2024
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Objective: In Japan, the current coverage rate of human papillomavirus (HPV) vaccination is only 30%, and the rate of biennial cervical screening is 40%. The Japanese Government has attempted to increase the coverage of HPV vaccination and cervical screening. We analyzed the cost-effectiveness of the 9-valent HPV vaccine and cervical screening in Japan.
View Article and Find Full Text PDF<b>Background and Objective:</b> Cervical cancer is the second most common cancer in Indonesia, where traditional herbal treatments like <i>Zanthoxylum acanthopodium</i> (andaliman) are culturally used. Investigating protein biomarkers such as E7, pRb, EGFR and p16 can help assess the efficacy of these treatments. <b>Materials and Methods:</b> There were 5 groups in this study: 2 control groups (C- and C+) and 3 treatment groups (each receiving one of three doses).
View Article and Find Full Text PDFDetecting epithelial-mesenchymal transition signaling molecules in cervical epithelial cells aids in the early diagnosis of cervical lesions.
BMC Cancer
December 2024
Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Background: This study aimed to investigate the potential utility of Epithelial-mesenchymal transition (EMT) signaling cell detection in the early diagnosis of cervical lesions.
Methods: Enrichment of cervical epithelial cells was carried out using a calibrated membrane with 8-μm diameter pores. RNA-in situ hybridization (RNA-ISH) was employed to detect and characterize EMT cells utilizing specific EMT markers.
The Assessment of Knowledge About Cervical Cancer, HPV Vaccinations, and Screening Programs Among Women as an Element of Cervical Cancer Prevention in Poland.
J Pers Med
December 2024
School of Public Health, Centre of Postgraduate Medical Education of Warsaw, 01-826 Warsaw, Poland.
: Cervical cancer is the fourth most commonly diagnosed malignant tumor in women and the fourth leading cause of cancer-related deaths among this population. Since it is asymptomatic in its early stages, preventive screening plays a crucial role in rapid diagnosis. Such screenings are conducted in many countries worldwide, although their popularity varies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!